hydrochlorothiazide has been researched along with Pseudohypoparathyroidism in 2 studies
Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.
hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.
Pseudohypoparathyroidism: A hereditary syndrome clinically similar to HYPOPARATHYROIDISM. It is characterized by HYPOCALCEMIA; HYPERPHOSPHATEMIA; and associated skeletal development impairment and caused by failure of response to PARATHYROID HORMONE rather than deficiencies. A severe form with resistance to multiple hormones is referred to as Type 1a and is associated with maternal mutant allele of the ALPHA CHAIN OF STIMULATORY G PROTEIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the effect of orally administered 100 mg of hydrochlorothiazide (HCTZ) among eight patients with pseudohypoparathyroidism (PHP) type I, 11 patients with idiopathic hypoparathyroidism (IHP), and 12 patients with primary hyperparathyroidism (1'HPT)." | 7.69 | The modulatory effect of endogenous parathyroid hormone on the action of hydrochlorothiazide in pseudohypoparathyroidism type I. ( Abe, K; Furukawa, Y; Mizunashi, K; Yoshinaga, K, 1994) |
| "We compared the effect of orally administered 100 mg of hydrochlorothiazide (HCTZ) among eight patients with pseudohypoparathyroidism (PHP) type I, 11 patients with idiopathic hypoparathyroidism (IHP), and 12 patients with primary hyperparathyroidism (1'HPT)." | 3.69 | The modulatory effect of endogenous parathyroid hormone on the action of hydrochlorothiazide in pseudohypoparathyroidism type I. ( Abe, K; Furukawa, Y; Mizunashi, K; Yoshinaga, K, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alon, U | 1 |
| Costanzo, LS | 1 |
| Chan, JC | 1 |
| Mizunashi, K | 1 |
| Furukawa, Y | 1 |
| Abe, K | 1 |
| Yoshinaga, K | 1 |
2 other studies available for hydrochlorothiazide and Pseudohypoparathyroidism
| Article | Year |
|---|---|
Additive hypocalciuric effects of amiloride and hydrochlorothiazide in patients treated with calcitriol.
Topics: Absorption; Adolescent; Adult; Amiloride; Calcitriol; Calcium; Child; Child, Preschool; Diuretics; D | 1984 |
The modulatory effect of endogenous parathyroid hormone on the action of hydrochlorothiazide in pseudohypoparathyroidism type I.
Topics: Administration, Oral; Adolescent; Adult; Aged; Calcium; Cyclic AMP; Female; Humans; Hydrochlorothiaz | 1994 |